GSK is licensing out the liver disease drug linerixibat to the Italian pharma Alfasigma for $300 million upfront, weeks ahead of the pill’s March 24 PDUFA date.
The drug, which is …
Welcome to another edition of Endpoints Weekly — and happy spring! The weather may not feel very spring-like here in NYC (outside that false start
The FDA is seeking feedback ahead of a public meeting this summer to evaluate the progress of a voucher pilot that has so far accelerated
The lead drug pricing negotiator at the White House said the overarching goal of TrumpRx is to improve price transparency, not to be a large
Plus, news about Gilead, Assembly Biosciences and Pfizer: 📁 Sarepta says FDA open to a filing for full approval of two Duchenne drugs: After a
The US-headquartered, China-rooted biotech Earendil Labs said it has raised $787 million in private money, a whopping sum to fund an AI platform that has
GSK is licensing out the liver disease drug linerixibat to the Italian pharma Alfasigma for $300 million upfront, weeks ahead of the pill’s March 24 PDUFA date.
The drug, which is …